Summary: This ADC product is comprised of an anti-CD22 monoclonal antibody (10F4v3) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. http://www.creative-biolabs.com/adc/target-cd22-10.htm